Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is expected to continue its robust growth with a diversified pipeline, including the recent acquisition of Japan rights to safusidenib, and cash on hand to fund operations in the near term. The company has a differentiated product in taletrectinib, with potential for fast-track approval due to its potential in treating ROS1+ NSCLC, and promising PRO data for its TRUST-IV study. There are risks to consider, including clinical trial delays and potential competition, but the company's current valuation presents an attractive opportunity for investors.

Bears say

Nuvation Bio is expected to generate revenue primarily from out-licensing collaborative agreements, with a specific focus on its product candidate, taletrectinib, for the treatment of ROS1+ non-small cell lung cancer (NSCLC). However, the company's quarterly new patient starts in 1Q26 only accounted for ~13% penetration of the estimated ~3,000 newly diagnosed ROS1+ NSCLC patients annually, indicating slower than expected adoption trends and potential competition from other therapies. Furthermore, potential risks include delays in trial enrollment and regulatory approvals, and the emergence of better-than-expected competitor products, which may hinder the company's ability to meet its revenue projections.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.